Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Melanoma Institute Australia
Scientific Title
A Phase II, Randomised, Open Label Study of Neoadjuvant Dabrafenib, Trametinib and / or Pembrolizumab in BRAF V600 Mutant Resectable Stage IIIB/C Melanoma